Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents evidence for intervention before allogeneic stem-cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) with detectable measurable residual disease (MRD). Dr Kadia highlights that pre-transplant MRD positivity is linked to higher relapse risk and inferior survival. He also emphasizes the potential of effective upfront therapy, such as the cladribine, low-dose cytarabine and venetoclax regimen (NCT03586609), to eradicate MRD, highlighting that clearing MRD, as seen in studies including RELAZA2 (NCT01462578), is associated with improved outcomes. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.